Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 506-515, 2005. First published January 13, 2005; 10.1373/clinchem.2004.042341
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
clinchem.2004.042341v1
51/3/506    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michael, I. P.
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michael, I. P.
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2005;51:506-515.)
© 2005 American Association for Clinical Chemistry, Inc.


Molecular Diagnostics and Genetics

Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family

Iacovos P. Michael1,2, Lisa Kurlender1,2, Nader Memari1,2, George M. Yousef3, Daisy Du1, Linda Grass1, Carsten Stephan4, Klaus Jung4 and Eleftherios P. Diamandis1,2,a

1 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
3 Discipline of Pathology, Memorial University, St. John’s, NL, Canada.
4 Urology, University Hospital Charité, Humboldt University, Berlin, Germany.

aAddress correspondence to this author at: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, ON, Canada M5G 1X5. Fax 416-586-8628; e-mail ediamandis{at}mtsinai.on.ca.

Background: All human kallikrein (KLK) genes have at least one splice variant, some of which possess clinical utility in cancer diagnostics/prognostics. Given that introns <100 bp in length are retained in 95% of human genes and that splice variants of KLK3 and KLK4 retain intron III, we hypothesized that other proteins in this family, with a small intron III, may also retain it.

Methods: Variant-specific reverse transcription-PCRs (RT-PCRs) for KLK1, KLK2, KLK5, and KLK15 were used to identify and clone the full coding sequence of intron III-containing splice variants. In addition, variant-specific RT-PCRs for the cloned KLK3 and KLK4 variants as well as for the "classical" forms of the six genes were used to determine their expression profiles in healthy tissues, their regulation by steroids, and their differential expression in prostate cancer.

Results: KLK1, KLK2, KLK3, KLK4, KLK5, and KLK15 showed a common type of splice variant in which intron III is retained. Expression profiling of these splice variants revealed expression profiles similar to those of the classical mRNA forms, although the pattern of hormonal regulation was different. The KLK15 splice variant was up-regulated in 8 of 12 cancerous prostate tissues. All encoded variant proteins were predicted to be truncated and catalytically inactive because of a lack of the serine residue of the catalytic triad.

Conclusions: The first six centromeric members of the KLK gene family have splice variants that retain intron III. Some variants show tissue-specific expression. The KLK15 splice variant appears to be a candidate biomarker for prostate cancer.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
J. L.V. Shaw and E. P. Diamandis
Distribution of 15 Human Kallikreins in Tissues and Biological Fluids
Clin. Chem., August 1, 2007; 53(8): 1423 - 1432.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
L. Holzscheiter, J. C. Biermann, M. Kotzsch, P. Prezas, J. Farthmann, G. Baretton, T. Luther, V. C.G. Tjan-Heijnen, M. Talieri, M. Schmitt, et al.
Quantitative Reverse Transcription-PCR Assay for Detection of mRNA Encoding Full-Length Human Tissue Kallikrein 7: Prognostic Relevance of KLK7 mRNA Expression in Breast Cancer
Clin. Chem., June 1, 2006; 52(6): 1070 - 1079.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.